Lomitapide: a novel drug for homozygous familial hypercholesterolemia

  title={Lomitapide: a novel drug for homozygous familial hypercholesterolemia},
  author={Maria D. Panno and Angelo B. Cefal{\`u} and Maurizio Rocco Averna},
  journal={Clinical Lipidology},
  pages={19 - 32}
Abstract Lomitapide (Juxtapid® and Lojuxta®; Aegerion Pharmaceuticals, Inc., MA, USA), an orally administered inhibitor of the microsomal triglyceride transfer protein, inhibits the synthesis and secretion of ApoB‑containing lipoproteins and, thus, reduces plasma levels of low‑density lipoprotein cholesterol (LDL‑C). Lomitapide has been approved for the therapy of homozygous familial hypercholesterolemia patients. After a proof‑of‑concept Phase II trial, lomitapide has been tested in a… 
Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide.
Lomitapide represents an innovative and efficacious drug for the treatment of HoFH and long-term safety data, treatment of pediatric and pregnant HoFH patients and management of severe hypertriglyceridemia still requires further investigations.
Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
It is suggested that lomitapide can be a drug of choice in patients with homozygous FH, as it contributed to improved LDL-C levels, a reduction in LDL apheresis sessions and enhanced quality of life.
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Role of the Gut in Diabetic Dyslipidemia
The intricacies of intestinal CM production are an active area of research that may yield novel therapies to prevent atherosclerotic CVD in insulin resistance and T2D and the molecular mechanisms underlying these effects are discussed.
Synthetic approaches to the 2013 new drugs.


LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia.
The lowering of LDL-cholesterol and other cardioprotective effects of LDL apheresis have reduced chest pain, prevented new disability and prolonged life and Whole blood compatible columns in development offer the possibility of simpler and less expensive treatments.
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
In a randomized trial involving patients with primary hypercholesterolemia, adding SAR236553 to either 10 mg of atorvastatin or 80 mg of least-squares mean (±SE) percent reduction in LDL cholesterol resulted in a significantly greater reduction in cholesterol than that attained with 80mg of atOrvastasin alone.
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Inhibition of LDL production with low-dose AEGR-733, either alone or in combination with ezetimibe, could be an effective therapeutic option for patients unable to reach target LDL-cholesterol levels.
Recommendations for the use of LDL apheresis.